Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1165]
News [3108]
Articles [128]
Editorials [5]
Conferences [139]
elearning [16]
Hallmarks of cancer cell development
Dr Douglas Hanahan - Swiss Institute for Experimental Cancer Research, Lausanne...
Hallmarks of cancer cell development ( Dr Douglas Hanahan - Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland )
27 Apr 2017
Avelumab for metastatic Merkel cell carcinoma after chemotherapy
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Avelumab for metastatic Merkel cell carcinoma after chemotherapy ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017
Nivolumab and ipilimumab combination for advanced skin cancer
Dr James Larkin - The Royal Marsden, London, UK
Nivolumab and ipilimumab combination for advanced skin cancer ( Dr James Larkin - The Royal Marsden, London, UK )
12 Apr 2017
Long-term clinical outcomes and analyses of atezolizumab for mTNBC
Prof Peter Schmid - Barts Cancer Institute, London, UK
Long-term clinical outcomes and analyses of atezolizumab for mTNBC ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
12 Apr 2017
Durable responses to avelumab in patients with Merkel cell carcinoma
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Durable responses to avelumab in patients with Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker...
Prof Peter Schmid - Barts Cancer Institute, London, UK
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
11 Apr 2017
Five-year follow-up of nivolumab in NSCLC
Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Five-year follow-up of nivolumab in NSCLC ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
11 Apr 2017
Final overall survival analysis of MONARCH 1
Dr Hope Rugo - UCSF Medical Center, San Francisco, USA
Final overall survival analysis of MONARCH 1 ( Dr Hope Rugo - UCSF Medical Center, San Francisco, USA )
11 Apr 2017
Redefining tamoxifen for breast cancer
Gokul Das - Roswell Park Cancer Institute, Buffalo, USA
Redefining tamoxifen for breast cancer ( Gokul Das - Roswell Park Cancer Institute, Buffalo, USA )
11 Apr 2017
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid...
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
Neratinib in HER2 or HER3 mutant solid tumours
Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA
Neratinib in HER2 or HER3 mutant solid tumours ( Dr David Hyman - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Apr 2017
75 years of Tata Memorial Centre
Dr Rajendra Badwe - Tata Memorial Centre, Mumbai, India
75 years of Tata Memorial Centre ( Dr Rajendra Badwe - Tata Memorial Centre, Mumbai, India )
29 Mar 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation